Olmesartan Medoxomil Amarox

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil Amarox, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diastolic heart failure: assists in managing fluid overload and improving cardiac output. - Post‑myocardial infarction: supports long‑term blood pressure control to lower recurrence risk.

Adverse reactions to olmesartan medoxomil are generally mild to moderate and vary among patients.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhoea

Serious or Rare Side Effects: - Angio‑ema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation

Olmesartan medoxomil should be used with caution in several clinical situations.

- Renal impairment: dose may need adjustment and renal function monitored. - Hepatic impairment: use with caution and monitor liver enzymes. - Electrolyte disturbances: watch for hyperkalaemia, especially with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Concomitant use with aliskiren: avoid in patients with diabetes or renal impairment. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan medoxomil can interact with several other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren (in diabetic or renal‑impaired patients): may increase risk of renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): can cause dangerous hyperkalaemia. - NSAIDs (high‑dose ibuprofen, naproxen): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors: combined use raises risk of hypotension, hyperkalaemia, and renal impairment. - Lithium: may increase serum lithium levels, risking toxicity. - Diuretics (thiazides): may enhance antihypertensive effect and affect electrolyte balance.